Starting a Biologic for Chronic Spontaneous Urticaria: Benefits, Side Effects, and Questions to Ask Your Doctor

TL;DR

• For chronic spontaneous urticaria (CSU) that remains uncontrolled despite antihistamines, omalizumab is an established add-on biologic treatment. It targets immunoglobulin E (IgE).\[2,3\]
• Some patients notice improvement quickly, while others need several doses before the benefit becomes clear. The 2026 international urticaria guideline specifically notes that onset can sometimes be slow.\[2\]
• Omalizumab is generally well tolerated. Common reported side effects include headache and injection-site reactions. Rare serious allergic reactions, including anaphylaxis, can occur.\[3,4\]
• In mama health's patient conversations about starting omalizumab, the biggest unanswered questions were often not about the injection itself. Patients wanted to know how long treatment would last, what happens after stopping, and what options exist if it does not work.\[1\]
• Starting a biologic can be an important turning point, but it is not always the end of the CSU treatment journey. Response, disease control and the need for continued treatment should be reassessed with a healthcare professional.

What is a biologic treatment for chronic spontaneous urticaria?

A biologic is a medicine designed to act on a specific part of the immune system involved in disease activity.

For CSU, the biologic with the longest-established role is omalizumab, also known by the brand name Xolair. Omalizumab is a monoclonal antibody that targets IgE.

The European Medicines Agency authorises omalizumab as an add-on treatment for adults and adolescents aged 12 years and over with CSU that has not responded adequately to H1-antihistamines.\[3\]

The 2026 international urticaria guideline recommends an initial CSU dose of 300 mg every four weeks as an add-on to antihistamine treatment. Individual prescribing decisions remain the responsibility of the treating healthcare professional.\[2\]

The biologic landscape is also changing. Dupilumab, which targets IL-4 and IL-13 signalling, is now authorised in the EU for moderate-to-severe CSU in patients aged 2 years and older whose disease is inadequately controlled with H1-antihistamines and who have not previously received anti-IgE treatment for CSU.\[6\]

Because mama health's patient data supplied for this article concern omalizumab initiation specifically, most of this article focuses on omalizumab rather than biologics as a single interchangeable category.

When might a biologic be discussed for CSU?

A biologic may be discussed when CSU remains inadequately controlled despite appropriate use of second-generation H1-antihistamines.

Current guidelines recommend a stepwise treatment approach. Second-generation antihistamines are used first. If the standard dose does not provide adequate control, the guideline recommends considering updosing one second-generation antihistamine up to four times the standard dose before escalating further. This higher dosing is off-label.\[2\]

Omalizumab is a major next treatment step when high-dose antihistamine treatment is insufficient.\[2\]

For many patients, however, reaching this point feels less orderly than the treatment algorithm suggests. A meaningful share of the patients in mama health's Italian CSU conversations had reached omalizumab in their treatment pathway.\[1\]

Looking specifically at the patients who discussed starting omalizumab, a clear pattern emerged in what typically came before the first injection:

• years of recurring hives or angioedema;
• multiple antihistamine trials;
• high-dose antihistamine use;
• repeated corticosteroid rescue;
• disrupted sleep;
• withdrawal from work or social activities;
• and uncertainty about what could still help.\[1\]

The biologic conversation therefore often arrived after a long period of treatment fatigue rather than as simply "the next medicine."

How do patients feel before starting omalizumab?

Patients commonly describe a mixture of exhaustion, hope and fear before their first injection.

Across the patients mama health spoke with about starting treatment, recurring emotions included desperation, isolation and cautious optimism.\[1\]

Some patients hoped treatment would finally allow them to sleep normally, work consistently, exercise again or make social plans without anticipating another flare.

At the same time, many expressed concern about starting a biologic. A common question was essentially: "Am I solving one problem by creating another?" Fear of unknown long-term effects came up repeatedly in the patient accounts.\[1\]

That concern deserves a clear conversation rather than simple reassurance. Patients can ask why a particular biologic is being considered, what is known about its safety, which side effects require attention and how continued treatment will be reviewed.

What benefits can omalizumab provide for CSU?

Omalizumab can reduce wheals, itching and angioedema and improve quality of life in people with antihistamine-refractory CSU.

The current international guideline describes omalizumab as effective at preventing wheals and angioedema and improving quality of life. It also considers omalizumab suitable for long-term treatment when clinically appropriate.\[2\]

Patients often describe the benefits in less clinical terms. Some patients told mama health they noticed a meaningful reduction in itch and hives within days or weeks after beginning treatment. Several described sleeping properly for the first time in years.\[1\]

But symptom reduction was not always the benefit they valued most. Patients frequently talked about being able to return to work, exercise again, sleep without repeatedly waking because of itch, make plans without worrying about visible wheals, wear clothes they had previously avoided, and participate in social activities again.\[1\]

For these patients, treatment success meant getting parts of everyday life back, not only achieving a better symptom score.

How quickly does omalizumab work for chronic spontaneous urticaria?

Omalizumab does not work at the same speed for everyone.

Some patients described noticeable improvement after the first injection or within several weeks. Others needed multiple doses before they felt confident that treatment was helping.\[1\] The 2026 international guideline also cautions that omalizumab's onset of action can be slow in some patients.\[2\]

This variation can make the first few months emotionally difficult. A person who has heard someone else describe omalizumab as "life-changing after one injection" may worry if their own hives continue after the first dose. Another person may improve gradually rather than suddenly.

A slower response does not by itself establish whether the treatment will ultimately work.

Before beginning treatment, it can therefore be useful to ask the treating clinician:

• When will we first assess my response?
• What would count as an adequate response?
• How long would we usually continue before deciding that the treatment has not worked well enough?
• How will we measure changes in hives, itch, swelling and daily life?

Clear expectations can make the waiting period easier to understand.

What are the common side effects of omalizumab?

Common side effects of omalizumab include headache and reactions around the injection site.

The European Medicines Agency lists headache and injection-site reactions such as pain, swelling, redness and itching among common adverse effects. In patients with CSU, other commonly reported effects include joint pain, sinusitis and upper respiratory tract infections.\[3\]

mama health's patient accounts were broadly consistent with a treatment that many people found tolerable. Most did not describe major adverse effects. When patients did mention physical effects after injections, the recurring themes included soreness or reaction around the injection site, headache, and fatigue in the days after treatment.\[1\]

Patient-reported symptoms cannot establish whether a medicine caused a particular effect, but they can show what people notice and what they may want to discuss during follow-up appointments.

Can omalizumab cause a serious allergic reaction?

Serious allergic reactions, including anaphylaxis, are a recognised but uncommon risk of omalizumab.

The EMA risk-management documentation identifies anaphylaxis and anaphylactoid reactions as important known risks. Post-marketing estimates cited by the EMA place reported anaphylaxis at approximately 0.2% of exposed patients, although post-marketing reporting has limitations.\[4\]

This is one reason healthcare teams provide instructions about what to watch for after treatment and how injections should be administered.

Before starting, patients could ask:

• What signs of an allergic reaction should I recognise?
• Will I need to remain at the clinic after my injection?
• Could injections eventually be given outside the clinic in my situation?
• Who should I contact if I develop concerning symptoms after leaving?

The answers can differ between individuals and healthcare systems.

Are hives returning before the next injection a side effect?

Hives returning before the next scheduled injection are better described as possible incomplete disease control rather than a recognised side effect of omalizumab.

This distinction appeared repeatedly in what patients told mama health. Some reported doing well after an injection but noticing itch or hives returning during the third or fourth week of the monthly cycle.\[1\] Patients sometimes described this as a problem "caused by the injection wearing off."

Medically, several different situations could produce that experience. Symptoms may never have been completely controlled, may fluctuate naturally, or may return toward the end of the dosing interval.

The international guideline recognises that some patients do not obtain enough benefit from omalizumab at the licensed dose. Specialist-led use of higher doses, shorter treatment intervals or both has been studied, although these approaches are off-label.\[2\]

Patients should not change the dose or timing independently. Instead, documenting when symptoms return in relation to each injection can provide useful information for a healthcare professional.

How long do you stay on omalizumab for CSU?

There is no single treatment duration that applies to every person with CSU.

This was the most prominent information gap in what patients shared with mama health. Again and again, patients asked: "How long will I be on this?"\[1\] For many, the uncertainty was more stressful than the injection.

The 2026 guideline describes omalizumab as suitable for long-term treatment and notes that treatment can be adjusted according to disease control. It discusses extending the interval in people who have maintained complete control, although interval changes outside the authorised schedule are off-label.\[2\]

A World Allergy Organization position paper on CSU remission and treatment reduction concluded that there is still no universally established best time to step down therapy. It suggested that treatment reduction may reasonably be considered after around six months of disease control, followed by reassessment, but emphasised the limits of the available evidence.\[5\]

This means the duration conversation should ideally begin before treatment starts, even if the exact endpoint cannot yet be predicted. Useful questions include:

• What would make us continue treatment?
• What level of control would make us consider reducing treatment?
• How often will we reassess whether I still need it?
• Is there a planned review point rather than an automatic stop date?

What happens if you stop omalizumab?

CSU symptoms can return after omalizumab is stopped, although what happens varies between individuals.

The international guideline notes that omalizumab can be effective again when CSU relapses after discontinuation.\[2\]

A return of symptoms after stopping does not necessarily mean that the medicine caused a "rebound." It may instead mean that the underlying CSU was still active when treatment was removed. This distinction matters because relapse and medication withdrawal are not the same thing.

Stopping treatment was a major source of anxiety in what patients told mama health. People who had finally regained sleep, work capacity or social confidence were understandably worried about losing that stability.\[1\]

Instead of waiting until discontinuation becomes imminent, patients could ask at the beginning:

• Under what circumstances would we consider stopping?
• Would treatment be stopped suddenly or adjusted gradually?
• What would we do if hives returned?
• How quickly should I contact the clinic if symptoms recur?
• Would restarting the same treatment be possible?

Having a plan can reduce uncertainty even when the future course of CSU cannot be predicted.

What do we know about the long-term safety of omalizumab?

Omalizumab has accumulated substantial clinical experience, but patients should still understand what is known and what remains less certain specifically for long-term CSU treatment.

The 2026 international guideline considers omalizumab suitable for long-term CSU treatment.\[2\]

At the same time, the EMA's CSU overview notes that controlled data extending beyond six months are more limited than shorter-term evidence. Safety information continues to be monitored after authorisation, as it is for other medicines.\[3\]

These statements are not contradictory. A medicine can have substantial accumulated clinical use while evidence for particular treatment durations, patient groups or long-term CSU-specific outcomes remains less extensive than short-term trial evidence.

Patients who are concerned about long-term treatment could ask:

• How long has this medicine been used for CSU?
• What long-term safety information is available?
• Are there particular risks relevant to my medical history?
• Do I need any tests or follow-up while receiving treatment?
• How often will the need for continued treatment be reviewed?

Why does the cause of CSU still matter after starting a biologic?

Understanding CSU remains important because starting an effective treatment does not always answer the question patients have been asking from the beginning: "Why is this happening to me?"

CSU is driven by activation of mast cells in the skin, but the underlying mechanism is not identical in every patient.

Current international guidance recognises at least two autoimmune mechanisms: type I autoimmunity, sometimes called autoallergic CSU, and type IIb autoimmune CSU. In other people, the underlying mechanism remains unknown.\[2\]

This helps explain why "spontaneous" does not mean that symptoms are imaginary or simply caused by stress. It means the hives arise without a specific external trigger that consistently explains them.

Patients frequently told mama health they wished someone had addressed this question before focusing entirely on the next medication.\[1\] A healthcare professional can explain what investigation is appropriate based on symptoms and history. Current guidelines favour a focused diagnostic assessment rather than extensive testing for every possible trigger.\[2\]

What happens if omalizumab does not work?

An incomplete response to omalizumab does not necessarily mean that all CSU treatment options have been exhausted.

A small number of patients in mama health's data were recorded as stopping omalizumab for lack or loss of efficacy.\[1\] This shouldn't be read as a precise discontinuation rate — patient records differ in completeness, and reasons for stopping may not always have been documented.

However, the experience mattered in the qualitative journeys. Patients repeatedly said they wished they had known before starting what the next conversation might look like if omalizumab failed, only partly worked or later seemed less effective.\[1\]

Current guidelines recognise specialist-led omalizumab adjustment for inadequate responders, although dosing beyond the licensed regimen is off-label.\[2\] The broader treatment landscape is also changing.

Is dupilumab an option for CSU?

Dupilumab is now an EU-authorised biologic option for moderate-to-severe CSU in patients aged 2 years and older who have an inadequate response to H1-antihistamines and have not previously received anti-IgE therapy for CSU.\[6\] That last condition is important. Its current EU indication should not be interpreted as a universal next-line biologic after omalizumab.

Are there non-biologic options?

Yes. Remibrutinib is not a biologic. It is an oral Bruton's tyrosine kinase, or BTK, inhibitor. It received EU marketing authorisation on April 23, 2026 for adults with CSU whose disease has responded inadequately to H1-antihistamines.\[7\]

Other treatments, including ciclosporin in selected severe cases, may also enter specialist discussions depending on previous treatment, safety considerations, availability and local guidance.\[2\] The relevant next option is individual and should be discussed with a clinician familiar with CSU.

What practical burdens can come with biologic treatment?

For many patients, the practical burden of biologic treatment can be more frustrating than the injection itself.

Patients told mama health about travelling to specialist centres, arranging monthly appointments, taking time away from work, waiting for treatment, managing Piano Terapeutico renewals, and navigating AIFA-related administrative processes.\[1\] mama health's guide to urticaria centres of excellence in Italy can help with finding a specialist centre closer to home.

Several patients who tolerated the medicine well still described the access process as exhausting. This is an important part of treatment planning.

Before the first dose, useful practical questions may include:

• Where will the injections take place, and how frequently will I need to attend?
• Will I always need a hospital or specialist-centre appointment?
• What paperwork or treatment-plan renewals are required, and who handles authorisation and renewal?
• What happens if an appointment is delayed?
• Who should I contact about access problems?

For someone already managing unpredictable hives, knowing these details can make the treatment journey more manageable.

Who should you contact if you flare between biologic appointments?

Patients should know in advance which healthcare contact is appropriate if symptoms worsen between scheduled visits.

This was one of the clearest continuity-of-care gaps that came up in mama health's conversations with patients. Monthly appointments can leave long periods in which patients are unsure whether they should contact the specialist clinic, their general practitioner, an emergency service or simply wait until the next visit.\[1\] The question is particularly relevant for people with recurring angioedema or severe flares.

Before leaving the first appointment, patients could ask:

• Who is my contact between doses?
• Which symptoms should prompt me to contact the clinic?
• What should I do if my usual CSU symptoms suddenly become much worse?
• What is the agreed plan for severe flares?
• Where should I seek urgent help if I develop breathing difficulty or swelling involving the mouth or throat?

Sudden breathing difficulty, throat swelling or other signs of a severe allergic reaction require urgent medical attention.

What should you ask your doctor before starting a biologic for CSU?

The most useful questions cover not only how the treatment works, but also what happens months later. Based on mama health's patient conversations and current clinical guidance, patients could consider asking:

1. Why are you recommending this biologic for me?
2. What improvement should we realistically expect?
3. How long might it take before we know whether it is helping?
4. How will we measure whether my CSU is controlled?
5. What common side effects should I know about?
6. What rare but serious reactions should I recognise?
7. How long might I stay on treatment?
8. When will we review whether I still need it?
9. What happens if we eventually stop treatment?
10. What would we do if my symptoms returned?
11. What happens if the treatment only partially works?
12. What other options could be discussed if it does not work well enough?
13. What do we currently understand about the likely cause of my CSU?
14. Who should I contact if I flare between appointments?
15. What appointments, approvals or treatment-plan renewals should I expect?

These are conversation prompts rather than recommendations to start, stop or change a medicine.

What should you remember before your first biologic injection?

Starting a biologic for CSU can be a turning point, but it does not have to be treated as a finish line.

The patient experiences mama health has gathered suggest that people often begin omalizumab after months or years of disruption. Many are hoping for something much bigger than fewer wheals. They want sleep, predictability, work, exercise and a social life back.\[1\]

For some, improvement arrives quickly. For others, response takes longer or remains incomplete.

The recurring lesson from these conversations is that patients want the whole pathway explained at the beginning. They want to know not only "Could this help?" — they also want answers to "How long will I take it?", "What happens if I stop?", "What happens if it does not work?", and "Who helps me between appointments?"

Not every question has a definite answer at the first injection. But discussing the uncertainties openly can give patients a clearer understanding of what comes next.

Starting a biologic can be an important new stage in CSU care. It is still one stage of an ongoing treatment conversation.

Disclaimer: This content is informational and not medical advice. mama health offers information and support and does not replace a doctor.